CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Fresolimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01401062
NCT01401062Phase 2Completed
CompareCT.gov

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Weill Medical College of Cornell University·interventional·Posted Jul 25, 2011·Updated Mar 5, 2019

In Brief

A Phase 2 clinical trial evaluating Fresolimumab and Radiation Therapy for Metastatic Breast Cancer. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2011
Enrollment StartJul 1, 2011
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.9 years ago

Interventions

Fresolimumabdrug

Radiation Therapyradiation